ストックスクリーナーアプリを入手
0.00
100.00%
-0.0111
前日終値:
$0.0111
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$N/A
収益：
-
当期純損益:
$-12.07M
株価収益率:
0.00
EPS:
-10.6183
ネットキャッシュフロー:
$-16.71M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-99.74%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Compare VRPX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.00 | 0 | 0 | -12.07M | -16.71M | -10.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.10 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.91 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.30 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.91 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
289.65 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Virpax Pharmaceuticals Inc (VRPX) 最新ニュース
Comparing Virios Therapeutics (NASDAQ:VIRI) & Virpax Pharmaceuticals (NASDAQ:VRPX) - Defense World
VRPX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Petros Pharmaceuticals (NASDAQ:PTPI) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast - Defense World
Revenue per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView
Virpax reports positive study results for pain management drug - MSN
Virpax Pharmaceuticals to conduct reverse stock split - Intellectia AI
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
EBITDA per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
Virpax Pharmaceuticals Inc. (VRPX) Stock Price | Live Quotes & Charts | EXPM - StocksToTrade
Tangible book value per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
CapEx per share of Virpax Pharmaceuticals, Inc. – OTC:VRPX - TradingView — Track All Markets
RTW Biotech invests USD5.9 million in Yarrow Bioscience funding round - marketscreener.com
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Stocks advance as Nvidia earnings light up global markets - marketscreener.com
Wall Street opens higher as Nvidia test looms - marketscreener.com
Analyzing Virpax Pharmaceuticals (NASDAQ:VRPX) and IMV (OTCMKTS:IMVIQ) - Defense World
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Jones Expects Nasdaq to Climb Higher, Lower Rates - marketscreener.com
Virpax Pharmaceuticals, Inc.Common Stock (NQ: - FinancialContent
TNF Pharmaceuticals Regains Compliance With Nasdaq Listing Requirement - marketscreener.com
Hookipa Pharma to Voluntarily Delist From Nasdaq - marketscreener.com
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
VRPX Stock Price and Chart — OTC:VRPX - TradingView
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Reports on Progress of Envelta™ - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
Virpax receives positive Probudur™ results for dose range study - TradingView
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - Stock Titan
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com South Africa
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Nigeria
Star TribuneVirpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - FinancialContent
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering - Investing.com
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Virpax Pharmaceuticals names new board director - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals lowers quorum requirement By Investing.com - Investing.com Nigeria
Virpax Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
Dow Theory LettersSpartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering - FinancialContent
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug - Stock Titan
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy, Price Target is $173 - marketscreener.com
Virpax Pharmaceuticals Faces Nasdaq Delisting Risk - TipRanks
Virpax Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com
Virpax Pharmaceuticals extends financing negotiation rights By Investing.com - Investing.com UK
Virpax Pharmaceuticals announces auditor change and board resignation By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments - Business Wire
Virpax Pharmaceuticals Inc (VRPX) 財務データ
収益
当期純利益
現金流量
EPS
0.99%
0.71%
大文字化:
|
ボリューム (24 時間):